Icotinib - an orally available quinazoline-based inhibitor of epidermal growth factor receptor (egfr), with potential antineoplastic activity. Icotinib selectively inhibits the wild-type and several mutated forms of egfr tyrosine kinase. This may lead to an inhibition of egfr-mediated signal transduction and may inhibit cancer cell proliferation. Egfr, a receptor tyrosine kinase, has been upregulated in a variety of cancer cell types.
Up to date info
Latest research - Icotinib
|This medical article is a stub. You can help WikiMD by expanding it.|
Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on Icotinib for any updates.